OPKO Health (NASDAQ:OPK) Hits New 12-Month High – Should You Buy?

Shares of OPKO Health, Inc. (NASDAQ:OPK) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $2.04 and last traded at $1.94, with a volume of 15826287 shares trading hands. The stock had previously closed at $1.92.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on OPK shares. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Monday. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, February 28th.

OPKO Health Trading Up 1.0 %

The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -10.21 and a beta of 1.63. The business has a 50-day moving average of $1.56 and a two-hundred day moving average of $1.55.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. Research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $1.56 per share, with a total value of $780,000.00. Following the acquisition, the chief executive officer now directly owns 212,411,477 shares of the company’s stock, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders acquired a total of 1,389,971 shares of company stock worth $2,124,442 over the last quarter. Company insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in OPK. FMR LLC raised its position in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health in the 3rd quarter valued at $45,000. Cibc World Markets Corp bought a new stake in shares of OPKO Health during the fourth quarter worth $45,000. Zacks Investment Management bought a new stake in shares of OPKO Health during the fourth quarter worth $49,000. Finally, Private Advisor Group LLC lifted its stake in shares of OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,000 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.